Merrimack Pharmaceuticals, Inc. engages in discovering, developing and preparing to commercialize innovative medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer. Its offers its first commercial product, Onivyde, which is a novel encapsulation of the marketed chemotherapy drug irinotecan in liposomal formulation. The company was founded by Anthony J. Sinskey, Gavin MacBeath and Ulrik B. Nielsen in 1993 and is headquartered in Cambridge, MA.
Market Cap | 70.404 Million | Shares Outstanding | 13.41 Million | Avg 30-day Volume | 10.077 Thousand |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -0.06 |
Price to Revenue | 0.0 | Debt to Equity | 0.0 | EBITDA | -3.064 Million |
Price to Book Value | 5.7596 | Operating Margin | 0.0 | Enterprise Value | 78.15 Million |
Current Ratio | 21.486 | EPS Growth | 0.823 | Quick Ratio | 18.231 |
1 Yr BETA | 0.889 | 52-week High/Low | 7.41 / 3.66 | Profit Margin | 0.0 |
Operating Cash Flow Growth | 85.2557 | Altman Z-Score | 26.9927 | Free Cash Flow to Firm | -3.247 Million |
Please sign in first
18.7 Thousand total shares from 9 transactions
none
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
CROCKER GARY L SEE REMARKS |
|
123,549 | 2022-05-19 | 19 |
|
1,713,612 | 2022-01-28 | 4 | |
|
36,968 | 2022-01-24 | 2 | |
|
7,000 | 2021-06-10 | 1 | |
|
1,269,648 | 2021-04-14 | 0 | |
|
1,241,896 | 2019-07-24 | 0 | |
|
3,802 | 2019-07-16 | 0 | |
|
1,249,828 | 2019-06-28 | 0 | |
PETERS RICHARD PRESIDENT AND CEO |
|
0 | 2019-05-08 | 0 |
|
1,241,896 | 2019-04-15 | 0 | |
|
5,000 | 2019-03-13 | 0 | |
FRANCHI JEAN M. CHIEF FINANCIAL OFFICER |
|
0 | 2018-12-11 | 0 |
DRUMMOND DARYL C HEAD OF RESEARCH |
|
0 | 2018-12-11 | 0 |
MUNSIE JEFFREY A GENERAL COUNSEL |
|
0 | 2018-12-11 | 0 |
SANTILLANA SERGIO L. CHIEF MEDICAL OFFICER |
|
0 | 2018-12-11 | 0 |
|
0 | 2018-06-13 | 0 | |
|
0 | 2018-06-13 | 0 | |
|
0 | 2018-06-13 | 0 | |
|
0 | 2017-09-13 | 0 | |
|
0 | 2017-09-13 | 0 | |
|
0 | 2017-09-13 | 0 | |
NEEDHAM THOMAS E. JR. CHIEF BUSINESS OFFICER |
|
0 | 2017-08-01 | 0 |
GREEN JOHN L. PRINCIPAL ACCOUNTING OFFICER |
|
0 | 2017-06-14 | 0 |
STEWART EDWARD J. HEAD OF COMMERCIAL |
|
51,385 | 2016-07-26 | 0 |
SCHOEBERL BIRGIT M. HEAD OF DISCOVERY |
|
65,657 | 2016-07-25 | 0 |
MCCLEMENTS WILLIAM M. HEAD OF CORPORATE OPERATIONS |
|
14,072 | 2016-02-29 | 0 |
SULLIVAN WILLIAM A. PRINCIPAL ACCOUNTING OFFICER |
|
0 | 2016-02-08 | 0 |
MULROY ROBERT J. PRESIDENT AND CEO |
|
0 | 2016-02-08 | 0 |
LAIVINS PETER N HEAD OF DEVELOPMENT |
|
0 | 2016-02-08 | 0 |
AL-WAKEEL YASIR B. CFO AND HEAD OF CORP DEV |
|
0 | 2016-02-08 | 0 |
|
0 | 2015-05-13 | 0 | |
|
422,543 | 2014-12-18 | 0 | |
|
168,974 | 2014-06-02 | 0 | |
|
0 | 2014-05-13 | 0 | |
KHAN FAZAL R. SVP OF MANUFACTURING |
|
0 | 2014-02-11 | 0 |
NIYIKIZA CLET M. EVP OF DEVELOPMENT |
|
0 | 2013-03-12 | 0 |
|
84,033 | 2012-04-25 | 0 | |
|
954,519 | 2012-04-03 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CROCKER GARY L - Director - Officer SEE REMARKS see footnote |
2022-05-23 16:05:17 -0400 | 2022-05-19 | P | 512 | $5.04 | a | 123,549 | indirect | ||||||||
CROCKER GARY L - Director - Officer SEE REMARKS see footnote |
2022-05-19 16:05:14 -0400 | 2022-05-18 | P | 5,000 | $5.08 | a | 123,037 | indirect | ||||||||
CROCKER GARY L - Director - Officer SEE REMARKS see footnote |
2022-05-19 16:05:14 -0400 | 2022-05-17 | P | 225 | $5.10 | a | 118,037 | indirect | ||||||||
CROCKER GARY L - Director - Officer SEE REMARKS see footnote |
2022-05-16 16:05:17 -0400 | 2022-05-13 | P | 3 | $4.90 | a | 117,812 | indirect | -1.1742 | 0.0 | 1 | -1.1742 | 2 | |||
CROCKER GARY L - Director - Officer SEE REMARKS see footnote |
2022-05-16 16:05:17 -0400 | 2022-05-12 | P | 2,471 | $5.04 | a | 117,809 | indirect | -1.1742 | 0.0 | 1 | -1.1742 | 2 | |||
CROCKER GARY L - Director - Officer SEE REMARKS see footnote |
2022-04-25 16:05:11 -0400 | 2022-04-21 | P | 5,000 | $6.00 | a | 115,338 | indirect | 2.6009 | 4.2152 | 4.2152 | 6 | 0.0 | 1 | ||
CROCKER GARY L - Director - Officer SEE REMARKS see footnote |
2022-04-01 16:05:18 -0400 | 2022-03-31 | P | 300 | $6.18 | a | 110,338 | indirect | -0.314 | -1.7268 | -19.7802 | 11.9309 | 4 | -23.2339 | 27 | |
CROCKER GARY L - Director - Officer SEE REMARKS see footnote |
2022-04-01 16:05:18 -0400 | 2022-03-30 | P | 161 | $6.20 | a | 110,038 | indirect | -0.314 | -1.7268 | -19.7802 | 11.9309 | 4 | -23.2339 | 27 | |
CROCKER GARY L - Director - Officer SEE REMARKS see footnote |
2022-03-29 17:30:03 -0400 | 2022-03-28 | P | 5,000 | $6.16 | a | 109,877 | indirect | 2.0161 | 3.0645 | -16.129 | 15.0 | 7 | -21.129 | 30 |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
MERRIMACK PHARMACEUTICALS IN MACK | 2022-05-23 22:15:04 UTC | -0.1372 | 0.9572 | 1000000 |
MERRIMACK PHARMACEUTICALS IN MACK | 2022-05-23 21:45:03 UTC | -0.1372 | 0.9572 | 1000000 |
MERRIMACK PHARMACEUTICALS IN MACK | 2022-05-23 21:15:04 UTC | -0.1372 | 0.9572 | 1000000 |
MERRIMACK PHARMACEUTICALS IN MACK | 2022-05-23 20:45:03 UTC | -0.1829 | 1.0029 | 1000000 |
MERRIMACK PHARMACEUTICALS IN MACK | 2022-05-23 20:15:04 UTC | -0.1829 | 1.0029 | 1000000 |
MERRIMACK PHARMACEUTICALS IN MACK | 2022-05-23 19:45:04 UTC | -0.1829 | 1.0029 | 1000000 |
MERRIMACK PHARMACEUTICALS IN MACK | 2022-05-23 19:15:03 UTC | -0.1829 | 1.0029 | 1000000 |
MERRIMACK PHARMACEUTICALS IN MACK | 2022-05-23 18:45:03 UTC | -0.1829 | 1.0029 | 1000000 |
MERRIMACK PHARMACEUTICALS IN MACK | 2022-05-23 18:15:03 UTC | -0.1829 | 1.0029 | 1000000 |
MERRIMACK PHARMACEUTICALS IN MACK | 2022-05-23 17:45:03 UTC | -0.1829 | 1.0029 | 1000000 |
MERRIMACK PHARMACEUTICALS IN MACK | 2022-05-23 17:15:03 UTC | -0.1829 | 1.0029 | 1000000 |
MERRIMACK PHARMACEUTICALS IN MACK | 2022-05-23 16:45:03 UTC | -0.1088 | 0.9288 | 1000000 |
MERRIMACK PHARMACEUTICALS IN MACK | 2022-05-23 16:15:03 UTC | -0.1088 | 0.9288 | 1000000 |
MERRIMACK PHARMACEUTICALS IN MACK | 2022-05-23 15:45:04 UTC | -0.1088 | 0.9288 | 1000000 |
MERRIMACK PHARMACEUTICALS IN MACK | 2022-05-23 15:15:03 UTC | -0.1088 | 0.9288 | 1000000 |
MERRIMACK PHARMACEUTICALS IN MACK | 2022-05-23 14:45:03 UTC | -0.1088 | 0.9288 | 1000000 |
MERRIMACK PHARMACEUTICALS IN MACK | 2022-05-23 14:15:03 UTC | -0.1088 | 0.9288 | 1000000 |
MERRIMACK PHARMACEUTICALS IN MACK | 2022-05-23 13:45:03 UTC | -0.1088 | 0.9288 | 1000000 |
MERRIMACK PHARMACEUTICALS IN MACK | 2022-05-23 13:15:04 UTC | -0.1088 | 0.9288 | 1000000 |
MERRIMACK PHARMACEUTICALS IN MACK | 2022-05-23 12:45:03 UTC | -0.1088 | 0.9288 | 1000000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|